FP14.14 Post Hoc Analyses from an Open Label, Multi-Centre, ASTRIS Trial of Efficacy of Osimertinib for CNS Metastases with T790M-Positive Advanced NSCLC

Up to 40% of patients with epithelial growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) develop central nervous system(CNS) metastases throughout their disease. CNS metastasis has a negative impact on survival and quality of life including neurological dysfunction and cognitive impairment. However, the first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) have limited efficacy because of their limited blood-brain barrier permeability. Osimertinib, third-generation EGFR-TKI with selective activity for both sensitizing and EGFR T790M mutations, have showed higher CNS penetration ability over first- and second-generation EGFR-TKIs.